We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos Expands and Extends Drug Discovery Collaboration with Amgen
News

Galapagos Expands and Extends Drug Discovery Collaboration with Amgen

Galapagos Expands and Extends Drug Discovery Collaboration with Amgen
News

Galapagos Expands and Extends Drug Discovery Collaboration with Amgen

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Expands and Extends Drug Discovery Collaboration with Amgen"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced that its service division BioFocus DPI has expanded and extended its longstanding drug discovery collaboration with Amgen through 2007 and 2008.

As Galapagos has reported, the BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply biologically-directed library compounds to Amgen's discovery programs.

Under the terms of the extended agreement, Galapagos will receive an upfront fee of $2.4 million as a payment for 2007 research costs.

Additionally, Galapagos may receive compensation in the form of library and technology access fees, research fees, milestone payments, and bonuses.

The initial collaboration, announced in January 2003, involves the identification of lead candidates against multiple ion channel targets.

According to Galapagos, the agreement announced now expands this collaboration to include all classes of targets, including ion channel, GPCR and kinase targets.

Additionally, the agreement has been expanded to include the supply of BioFocus DPI's compound collection comprising 700,000 synthetic small molecules and its proprietary natural product compound collection containing 145,000 pre-purified subfractions, pure natural products, and semi-synthetic natural products.

"The additional breadth and depth gained by BioFocus DPI's drug discovery offering this year have helped us to expand our strong collaborative relationship with Amgen," said Onno van de Stolpe, Chief Executive Officer of Galapagos.

"We are excited that the potential hits arising from BioFocus DPI's unique library collections could provide promising lead candidates for Amgen's discovery programs over the next two years."

Advertisement